Discover your next big idea for life sciences at PACK EXPO Las Vegas
Experience a breakthrough in life sciences packaging—explore solutions from 2,300 suppliers spanning all industries, all in one place this September

U.S. is closer to first biosimilar

FDA officials see no difference between Neupogen and the biosimilar version.

Earlier this week documents from FDA reviewers decided that there are "no clinically meaningful difference" between Amgen's Neupogen, and Sandoz's biosimilar version, the Wall Street Journal reported.

Neupogen is used during chemotherapy to fight off infections.

According to the article, an FDA advisory committee is expected to be meeting Jan. 7, to review a marketing application filed for the drug.

Their decision could be market-changing.

"If approved, the Sandoz version would become the first biosimilar in the U.S., by way of a regulatory pathway that was created for these medicines three years ago," according to the article.

FDA warning letters surge - is your team prepared?
New guide reveals expert strategies to prevent regulatory issues and respond effectively to FDA enforcement actions in pharmaceutical and medical device manufacturing.
Read More
FDA warning letters surge - is your team prepared?
Pharmaceutical Innovations Report
Discover the latest breakthrough packaging technologies shaping the pharmaceutical sector. This report dives into cutting-edge innovations, from smart containers that enhance patient safety to eco-friendly materials poised to transform the industry’s sustainability practices. All from PACK EXPO. Learn how forward-thinking strategies are driving efficiency and redefining what’s possible in pharma packaging.
Learn More
Pharmaceutical Innovations Report